Witryna2 paź 2024 · Intercept Pharmaceuticals, Inc. announced that REVERSE, a Phase III study evaluating the safety and efficacy of OCA in patients with compensated cirrhosis due to nonalcoholic steatohepatitis (NASH), did not meet its primary endpoint of a greater than 1-stage histological improvement in fibrosis with no worsening of NASH following … WitrynaAlthough NASH has no approved treatments, obeticholic acid (OCA), a synthetic bile acid and farnesoid X receptor (FXR) agonist, was shown to improve histological features of …
Intercept Announces Withdrawal of EMA Marketing Authorization ...
Witryna21 cze 2024 · Abstract Obeticholic acid (OCA) and elafibranor (ELA) are selective and potent agonists for the farnesoid X receptor (FXR) and dual peroxisome proliferator-activated receptor α/δ (PPAR-α/δ), respectively. Both agents have demonstrated clinical efficacy in nonalcoholic steatohepatitis (NASH). Witryna2 dni temu · OCA has been rejected before in NASH, based on a key missed endpoint which was still not met after data was re-evaluated ahead of the latest NDA submission. OCA missed a key endpoint in a... european school science symposium
NASH - Intercept Pharmaceuticals
WitrynaKevin Nash, wrestling's six-time World Heavyweight Champion and twelve-time Tag Team Champion, is inviting YOU to become an insider in the most exclusive ban... Witryna234 Likes, 7 Comments - @_____nash on Instagram: "di fotoin oca gatau khansa, nuhun kang adit" Witryna25 lut 2024 · OCA was the first FXR ligand to progress to phase 3 clinical trials on NASH. However, side effects such as pruritus and dyslipidemia associated with OCA raise … first alert fa270kp user manual